Literature DB >> 22463980

Breaking the chain: Rift Valley fever virus control via livestock vaccination.

Brian H Bird1, Stuart T Nichol.   

Abstract

Rift Valley fever virus is a mosquito-borne pathogen of livestock and humans that causes widespread and devastating outbreaks of severe and often fatal disease throughout Africa and portions of the Arabian Peninsula. Outbreaks can involve tens to hundreds of thousands of human cases, and millions of livestock. The severity of the disease varies by species, but in sheep and cattle 'abortion storms', high neonatal (∼70%), and adult mortality (20-30%) are features. Human cases are generally self-limiting, but severe complications such as hepatitis, retinitis, delayed-onset encephalitis, or a hemorrhagic syndrome with a case fatality of 10-20% can occur. There are no commercially available human vaccines. Livestock provide key ecological links between the Aedes sp. mosquito vector and humans. High viremias in livestock lead to spillover of RVFV into other anthrophillic vectors (Culex and Anopheles sp. mosquitoes), and, importantly, close contact with infected animal tissues and fluids or aborted fetal materials from these animals is a major risk factor for severe and lethal human infections. Vaccination programs targeting livestock during non-epidemic periods or as an early countermeasure against nascent outbreaks could therefore eliminate one of the main sources of human infection and limit the overall scope of epidemics. To this end, research groups have recently reported novel next generation RVFV vaccines that are safe for use in pregnant and young animals. Preventing RVFV infection of livestock by vaccination is a key element in breaking the chain of human epidemics, and could lead to control of this significant public health threat. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22463980     DOI: 10.1016/j.coviro.2012.02.017

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  41 in total

1.  Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

Review 2.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

Review 3.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

Review 4.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

5.  The two faces of Rift Valley fever virus virulence factor NSs: The development of a vaccine and the elucidation of pathogenesis.

Authors:  Satoko Yamaoka; Hideki Ebihara
Journal:  Virulence       Date:  2016-07-18       Impact factor: 5.882

6.  Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets.

Authors:  Amy L Hartman; Diana S Powell; Laura M Bethel; Amy L Caroline; Richard J Schmid; Tim Oury; Douglas S Reed
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

7.  Serological surveillance studies confirm the Rift Valley fever virus free status in South Korea.

Authors:  Hyun Joo Kim; Jee-Yong Park; Hye-Young Jeoung; Jung-Yong Yeh; Yun-Sang Cho; Jeong-Soo Choi; Ji-Youn Lee; In-Soo Cho; Han-Sang Yoo
Journal:  Trop Anim Health Prod       Date:  2015-05-30       Impact factor: 1.559

Review 8.  Rift Valley Fever.

Authors:  Amy Hartman
Journal:  Clin Lab Med       Date:  2017-03-22       Impact factor: 1.935

Review 9.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

10.  Discovery of a unique novel clade of mosquito-associated bunyaviruses.

Authors:  Marco Marklewitz; Florian Zirkel; Innocent B Rwego; Hanna Heidemann; Pascal Trippner; Andreas Kurth; René Kallies; Thomas Briese; W Ian Lipkin; Christian Drosten; Thomas R Gillespie; Sandra Junglen
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.